Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.64 |
| ▸ | LOX | P28300 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20337978 | 0.99 | LOXL2 (0.66) | LOXL2LOXALDH1A1MMP13LMNA | |
| SCHEMBL18362036 | 0.89 | LOXL2 (0.73) | LOXL2LOXALDH1A1HTTKMT2A | |
| SCHEMBL18362177 | 0.87 | MMP13 (0.52) | LOXL2ALDH1A1MMP13LMNAHTT | |
| Hydrochloric Acid SCHEMBL20337850 | 0.86 | MMP13 (0.51) | LOXL2LOXALDH1A1MMP13LMNA | |
| SCHEMBL18362150 | 0.84 | LOXL2 (0.69) | LOXL2LOXMMP13 | |
| SCHEMBL18362048 | 0.84 | LOXL2 (0.63) | LOXL2LOXMAPK1 | |
| Hydrochloric Acid SCHEMBL20337968 | 0.83 | LOXL2 (0.71) | LOXL2LOXMMP13 | |
| Hydrochloric Acid SCHEMBL20337962 | 0.83 | LOXL2 (0.65) | LOXL2LOX | |
| SCHEMBL18362069 | 0.82 | LOXL2 (0.63) | LOXL2LOXMAPT | |
| SCHEMBL18362145 | 0.81 | LOXL2 (0.60) | LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| WO-2017003862-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885LOX 3/4885ALDH1A1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.